ArticleCell2025
CRATER tumor niches facilitate CD8
Abstract read
In one paragraph
Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Huchang-Barrier framework: an integrative perspective on the spatial features of the tumor invasive front.Medical review (2021) · 2026Article
- Mechanobiology of CAR-T cell therapy: regulatory mechanisms and strategies for enhanced antitumor immunity.Journal of translational medicine · 2026Review
- Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms.Cancers · 2026Review
- Comparison of Human Melanoma Single Cell Profiles to Evolutionary Medicine Model Xiphophorus Provides Insights in Disease Control.Pigment cell & melanoma research · 2026Article
- Spatial architecture of the melanoma immune niche reveals CORO1A as a functional hub for T cell cytotoxicity and immunotherapy synergy.Journal of translational medicine · 2026Article
- A plant vesicle-dendritic cell chimera for enhancing cancer immunotherapy.Nature communications · 2026Article
- A Hallmark-Integrated, Agent-Based Framework for Intratumor Heterogeneity in Melanoma Evolution.Bulletin of mathematical biology · 2026Article
- Turep: Detecting cross-cancer tumor-reactive T cells in single-cell and spatial transcriptomics data.bioRxiv : the preprint server for biology · 2026Article
- Sustained interferon exposure creates a hyper-metastatic subset of melanoma cells.bioRxiv : the preprint server for biology · 2026Article
- A CCL4-enriched NK-cell transcriptional state is associated with inflammatory and myeloid-stromal programs in colorectal cancer liver metastasis.Frontiers in immunology · 2026Article
- Single-cell transcriptomic profiling of halo nevi and normal nevi reveals CD8Frontiers in immunology · 2026Article
Corrections and comments
- Update of
Authors and funding
44 authors.
Aya LudinHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Georgia L StirtzHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Asaf TalHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Ajit J NirmalDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Kathleen L PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Michael ManosCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Naomi BessonCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Nebiyat EskndirCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Billie PorterCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Stephanie M JonesCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Hannah M FaulknerCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Qiyu GongBroad Institute of MIT and Harvard, Cambridge, MA 02139, USA.
Sophia LiuBroad Institute of MIT and Harvard, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Irving BarreraBroad Institute of MIT and Harvard, Cambridge, MA 02139, USA.
Lijian WuDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cecilia Pessoa RodriguesHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Aditi SahuDermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Elizabeth JerisonDepartment of Physics, University of Chicago, Chicago, IL 60637, USA.
Joao V AlessiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Biagio RicciutiLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Douglas S RichardsonHarvard Center for Biological Imaging, Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA.
Jodi D WeissHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Hadley M MoreauHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Meredith E StanhopeHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Alexander B AfeyanHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
James SeftonHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Wyatt D McCallHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Emily FormatoHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Song YangStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
Yi ZhouStem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
David P Hoytema van KonijnenburgDivision of Immunology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Hannah L ColeHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA.
Miguel CordovaDermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Liang DengDermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Milind RajadhyakshaDermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Stephen R QuakeDepartment of Bioengineering and Applied Sciences, Stanford University, Stanford, CA 94305, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Mark M AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Fei ChenHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Peter K SorgerLudwig Center at Harvard, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
F Stephen HodiCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Parker Institute for Cancer Immunotherapy, Boston, MA, USA.
Scott J RodigCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
George F MurphyDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Leonard I ZonHarvard Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: leonard.zon@enders.tch.harvard.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTranscriptional mechanisms and melanomaP01CA163222 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DAVID E FISHER · 2013 to 2026
$25.3MSuper-Resolution ImagingP30NS072030 · NINDS · HARVARD MEDICAL SCHOOL · PI REGEHR, WADE G · 2011 to 2020
$5.8MTherapeutic Targeting of Immune Evasion from the MICA - NKG2D PathwayR01CA238039 · NCI · DANA-FARBER CANCER INST · PI Kai W Wucherpfennig · 2019 to 2026
$4.2MEvaluating Pathways Involved in Melanoma InitiationR01CA295865 · NCI · BOSTON CHILDREN'S HOSPITAL · PI LEONARD Ira ZON · 2025 to 2026
$1.4MMechanisms of tumor microenvironmental regulation of T-cell infiltration in melanomaF31CA260802 · NCI · HARVARD MEDICAL SCHOOL · PI STIRTZ, GEORGIA · 2021 to 2023
$82kNCI NIH HHS F31 CA260802NCI NIH HHS P01 CA163222NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA238039NCI NIH HHS R01 CA295865NINDS NIH HHS P30 NS072030
Abstract
T cell-mediated tumor killing underlies immunotherapy success. Here, we used long-term in vivo imaging and high-resolution spatial transcriptomics of zebrafish endogenous melanoma, as well as multiplex imaging of human melanoma, to identify domains facilitating the immune response during immunotherapy. We identified cancer regions of antigen presentation and T cell engagement and retention (CRATERs) as pockets at the stroma-melanocyte boundaries of zebrafish and human melanoma. CRATERs are rich in antigen-recognition molecules, harboring the highest density of CD8
Indexed as
CD8-Positive T-LymphocytesImmunotherapyMelanomaTumor MicroenvironmentAnimalsAntigen PresentationCell Line, TumorHumansImmune Checkpoint InhibitorsZebrafishImmune Checkpoint InhibitorscancerCD8+ T cellsimmune responseimmunotherapymelanomazebrafish
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.